FRONTEO, Inc.
TTSE:2158703.00
JPY
+4.00
(+0.57%)
ISIN
JP3944630007
Return %
Stock
S&P 500
1Y
-27.60
14.20
3Y
14.87
81.12
5Y
-70.19
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Masahiro Morimoto
- Full Time Employees
- 272
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Meishan Takahama Building Tokyo TY Japan 108-0075
- IPO Date
- May 28, 2007
- Website
- fronteo.com
- Similar Companies
- Business
- FRONTEO, Inc. (2158.T) develops and provides specialized artificial intelligence (AI) solutions, primarily through its proprietary KIBIT engine, focusing on natural language processing for legaltech, life sciences, business intelligence, economic security, and digital transformation across Japan, the United States, Korea, and other international markets. Founded in 2003 and headquartered in Tokyo, Japan, the company offers core products and services including e-discovery support and forensic investigation tools such as Lit i View, KIBIT Automator, and digital forensics software; AI-powered business intelligence solutions like Communication Meter for email and chat audits, WordSonar for risk prediction and voice-of-customer analysis, Patent Explorer for patent searches, Knowledge Probe for data analysis, and KIBIT Eye for fraud detection; life science AI applications encompassing Drug Discovery AI Factory (DDAIF) for target identification, biomarker discovery, and drug repositioning, Concept Encoder for medical data analysis, and cognitive function testing devices like SDS-881; economic security tools including KIBIT Seizu Analysis for supply chain and shareholder network analysis; and DX solutions via Takumi KIBIT Zero integrated with Mendix for manufacturing data management. Targeting enterprises in finance, pharmaceuticals, manufacturing, law firms, and government agencies, FRONTEO operates subsidiaries such as FRONTEO USA, Inc., FRONTEO Korea, Inc., and the recently acquired Alnetz, Inc. In recent developments, the company completed the acquisition of Alnetz, Inc. in April 2025 to bolster DX offerings in manufacturing; launched seven co-creation projects under DDAIF with partners including UBE Corporation, Eisai, EA Pharma, Chugai Pharmaceutical, Maruishi Pharmaceutical, and Daiichi Sankyo for AI drug discovery support, exceeding FY24 targets; formed strategic alliances with TechnoPro R&D for drug development R&D, Institute of Science Tokyo and Kumamoto University for joint research on cancer treatments and new targets, and Mizuho Securities and MUFG Bank for KIBIT Eye compliance audits; secured US trademark registration for DDAIF and entered consulting agreements for US market expansion; reorganized segments effective FY25 into Life Science AI, Risk Management, and DX; and forecasted FY25 revenue of 7,000 million yen with operating income of 700 million yen, driven by transformational growth in life science AI and linear expansion in risk management and DX.